A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation

• Published in: Journal of translational medicine Vol. 19; no. 1; pp. 17 - 10
• Main Authors: Simeone, Ester, Scognamiglio, Giosuè, Capone, Mariaelena, Giannarelli, Diana, Grimaldi, Antonio M., Mallardo, Domenico, Madonna, Gabriele, Curvietto, Marcello, Esposito, Assunta, Sandomenico, Fabio, Sabbatino, Francesco, Bayless, Nicholas L., Warren, Sarah, Ong, SuFey, Botti, Gerardo, Flaherty, Keith T., Ferrone, Soldano, Ascierto, Paolo A.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.01.2021; BioMed Central; BMC
• Subjects: Adult; Adverse events; Animals; Antigens; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Azetidines; Biomarkers; Biopsy; BRAF inhibitor; Cell Cycle Proteins; Cloning; Drug therapy; Drug therapy, Combination; Gas1 protein; Genetic aspects; GPI-Linked Proteins; Humans; Immune response; Interferon; Interferons; Kinases; Lymphocytes; Malignant melanoma; MAP kinase; Melanoma; Melanoma - drug therapy; Melanoma - genetics; Metastasis; Mice; Mutation; Mutation - genetics; Peginterferon alfa-2a; Piperidines; Proto-Oncogene Proteins B-raf - genetics; Skin cancer; Skin Neoplasms - drug therapy; Testing; Vemurafenib; Vemurafenib - therapeutic use; α-Interferon; Italy; BRAF inhibitor; MAP kinase; Interferon; Malignant melanoma

Studies carried out in vitro and in a mouse model have shown that BRAF inhibitors enhance the effects of IFN-α on BRAFV600E melanoma cells through the inhibition of ERK. Therefore, the combination of vemurafenib and IFN-α in patients with BRAFV600E melanoma may provide therapeutic benefits; MEK inhi...